Transcutaneous Vagus Nerve Stimulation in Private Healthcare Center
CompletedNot applicableNCT03440255
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
This non-randomized, open-label study has the objective to study the effects and feasibility of Transauricular Vagus Nerve Stimulation (TaVNS) for patients suffering from Generalized Anxiety Disorder (GAD), Chronic Pain (CP) and Irritable Bowel Syndrome (IBS) in a private healthcare centre.
Study details
- Official title
- Transcutaneous Vagus Nerve Stimulation (TaVNS) in Private Healthcare Center: An Open-Label, Non-Randomized Feasibility Study Targeting Anxiety, Chronic Pain and Irritable Bowel Syndrome
- Conditions
- Generalized Anxiety Disorder
- Chronic Pain
- Irritable Bowel Syndrome
- Interventions
- Device: Transcutaneous Vagus Nerve Stimulation
- Sponsor
- Kinesis Health Associates
- Start date
- 2017-07-01
- Primary completion
- 2017-07-31
- Sex
- All
- Age range
- from 20 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Age range 20-65 years old 2. Patient suffering from either Generalized Anxiety Disorder, Chronic Pain scoring and Irritable Bowel Syndrome from moderate 3. Patients meet the scoring standard questionnaires: mild to severe 4. Patient can understand and answer the questions 5. Patient exhibits symptoms for at least six months Exclusion Criteria: 1. Reading difficulties 2. Diagnosed left ear lesion 3. Measured blood pressure under 100/60 with or without anti-high blood pressure medicine 4. Active implant such as cochlear implant 5. Wounds and skin disease in the left ear 6. Recent head trauma or concussion 7. Cardiac pacemaker 8. Severe alcoholism 9. Left cervical vagotomy 10. Cholinergic or B blocking medicine 11. Recreative drugs 12. Diagnosed concomitant psychiatric comorbidity 13. Diagnosed concomitant personal disorders 14. Diagnosed pregnancy 15. Diagnosed concomitant severe neurological or medical diseases such as neoplasms in activity, neurodegenerative diseases and chronic infectious diseases uncompensated
Canadian sites (1)
| Facility | City | Province |
|---|---|---|
| Kinesis Health Associates | Dartmouth | Nova Scotia |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03440255